Syros Pharmaceuticals, Inc. (SYRS)
NASDAQ: SYRS · Real-Time Price · USD
0.275
-0.015 (-5.19%)
Nov 21, 2024, 1:34 PM EST - Market open

Company Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.

The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals logo
Country United States
Founded 2011
IPO Date Jun 30, 2016
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Conley Chee

Contact Details

Address:
35 CambridgePark Drive, 4th Floor
Cambridge, Massachusetts 02140
United States
Phone 617 744 1340
Website syros.com

Stock Details

Ticker Symbol SYRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001556263
CUSIP Number 87184Q107
ISIN Number US87184Q2066
Employer ID 45-3772460
SIC Code 2834

Key Executives

Name Position
Conley Chee Chief Executive Officer, President and Director
Dr. Richard A. Young Ph.D. Scientific Founder, Member of Scientific Advisory Board and Director
Jason Haas Chief Financial Officer
Dr. David A. Roth M.D. Chief Medical Officer
Dr. James E. Bradner M.D. Founder
Dr. Nathanael S. Gray Ph.D. Scientific Founder and Member of Scientific Advisory Board
Karen Hunady M.S. Director of Corporate Communications and Investor Relations
Gerald E. Quirk Esq., J.D. Chief Legal and Compliance Officer and Chief Business Officer
Lisa Roberts Vice President of Human Resources
Kristin Stephens Chief Development Officer

Latest SEC Filings

Date Type Title
Nov 19, 2024 144 Filing
Nov 18, 2024 144 Filing
Nov 18, 2024 144 Filing
Nov 18, 2024 144 Filing
Nov 18, 2024 144 Filing
Nov 18, 2024 144 Filing
Nov 18, 2024 144 Filing
Nov 18, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals